Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions
Breast cancer (BC) is a malignancy with the highest incidence in women. Great progress has been made in research related to traditional precision medicine for BC. However, many reports have suggested that patients with BC have not benefited a lot from such progress. Thus, we analyze traditional prec...
Gespeichert in:
Veröffentlicht in: | Bioscience reports 2019-09, Vol.39 (9) |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 9 |
container_start_page | |
container_title | Bioscience reports |
container_volume | 39 |
creator | Zhang, Xiping Yang, Hongjian Zhang, Ruiping |
description | Breast cancer (BC) is a malignancy with the highest incidence in women. Great progress has been made in research related to traditional precision medicine for BC. However, many reports have suggested that patients with BC have not benefited a lot from such progress. Thus, we analyze traditional precision medicine strategies for BC, sum up their limitations and challenges, and preliminarily propose future orientations of precision medicine strategies based on a database on drug reaction of patients with BC. According to related research, traditional precision medicine strategies for BC, which are based on molecular subtypes, perform pertinent treatments, new drug research and development according to molecular typing results. Nevertheless, these strategies still have some deficiencies. First, there are very few patients with each molecular subtype, the match ratio of drugs is low. Second, these strategies can not solve the problem of poor drug sensitivity resulting from heterogeneity. The main strategy we put forward in the present paper is based on patients' varying drug reactions. Focusing on treating existing patients and maximizing the utilization of existing drugs, it is expected to not have deficiencies of traditional precision medicine for BC, including low match rate and poor therapeutic efficacy arising from tumor heterogeneity of BC. |
doi_str_mv | 10.1042/BSR20190230 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6732363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2269399363</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-a36c26ca9c2d2a9a249a8b189cbab300ac123562a750ec21413e5608a07ad95f3</originalsourceid><addsrcrecordid>eNpVkUlLBDEUhIMoOi4n75KjIK3ZeslF0MENBMHlHF6nX89EetJj0i34780wOujpUdRHvYIi5Jizc86UuLh-eRaMayYk2yITnpcyU1rm22TCuFJZpQq5R_ZjfGeMJUPtkj3JZVXqUkyIn86h69DPMFLwDW3HYQxI-5YuA1oXXe_pAhtnnUcahwADzlxi2z7QOiDEgVrwFpOCiA1NONAGBljJlWrCOKMJtEOKiodkp4Uu4tHPPSBvtzev0_vs8enuYXr1mFmlyiEDWVhRWNBWNAI0CKWhqnmlbQ21ZAwsFzIvBJQ5Qyu44hLzglXASmh03soDcrnOXY51qm_Rp-qdWQa3gPBlenDmv-Pd3Mz6T1OUUshCpoDTn4DQf4wYB7Nw0WLXgcd-jEaIQkut1-jZGrWhjzFgu3nDmVktZP4slOiTv8027O8k8hsMuI2Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2269399363</pqid></control><display><type>article</type><title>Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Zhang, Xiping ; Yang, Hongjian ; Zhang, Ruiping</creator><creatorcontrib>Zhang, Xiping ; Yang, Hongjian ; Zhang, Ruiping</creatorcontrib><description>Breast cancer (BC) is a malignancy with the highest incidence in women. Great progress has been made in research related to traditional precision medicine for BC. However, many reports have suggested that patients with BC have not benefited a lot from such progress. Thus, we analyze traditional precision medicine strategies for BC, sum up their limitations and challenges, and preliminarily propose future orientations of precision medicine strategies based on a database on drug reaction of patients with BC. According to related research, traditional precision medicine strategies for BC, which are based on molecular subtypes, perform pertinent treatments, new drug research and development according to molecular typing results. Nevertheless, these strategies still have some deficiencies. First, there are very few patients with each molecular subtype, the match ratio of drugs is low. Second, these strategies can not solve the problem of poor drug sensitivity resulting from heterogeneity. The main strategy we put forward in the present paper is based on patients' varying drug reactions. Focusing on treating existing patients and maximizing the utilization of existing drugs, it is expected to not have deficiencies of traditional precision medicine for BC, including low match rate and poor therapeutic efficacy arising from tumor heterogeneity of BC.</description><identifier>ISSN: 0144-8463</identifier><identifier>EISSN: 1573-4935</identifier><identifier>DOI: 10.1042/BSR20190230</identifier><identifier>PMID: 31387972</identifier><language>eng</language><publisher>England: Portland Press Ltd</publisher><subject>Review</subject><ispartof>Bioscience reports, 2019-09, Vol.39 (9)</ispartof><rights>2019 The Author(s).</rights><rights>2019 The Author(s). 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-a36c26ca9c2d2a9a249a8b189cbab300ac123562a750ec21413e5608a07ad95f3</citedby><cites>FETCH-LOGICAL-c447t-a36c26ca9c2d2a9a249a8b189cbab300ac123562a750ec21413e5608a07ad95f3</cites><orcidid>0000-0002-3556-9681</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732363/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732363/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31387972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Xiping</creatorcontrib><creatorcontrib>Yang, Hongjian</creatorcontrib><creatorcontrib>Zhang, Ruiping</creatorcontrib><title>Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions</title><title>Bioscience reports</title><addtitle>Biosci Rep</addtitle><description>Breast cancer (BC) is a malignancy with the highest incidence in women. Great progress has been made in research related to traditional precision medicine for BC. However, many reports have suggested that patients with BC have not benefited a lot from such progress. Thus, we analyze traditional precision medicine strategies for BC, sum up their limitations and challenges, and preliminarily propose future orientations of precision medicine strategies based on a database on drug reaction of patients with BC. According to related research, traditional precision medicine strategies for BC, which are based on molecular subtypes, perform pertinent treatments, new drug research and development according to molecular typing results. Nevertheless, these strategies still have some deficiencies. First, there are very few patients with each molecular subtype, the match ratio of drugs is low. Second, these strategies can not solve the problem of poor drug sensitivity resulting from heterogeneity. The main strategy we put forward in the present paper is based on patients' varying drug reactions. Focusing on treating existing patients and maximizing the utilization of existing drugs, it is expected to not have deficiencies of traditional precision medicine for BC, including low match rate and poor therapeutic efficacy arising from tumor heterogeneity of BC.</description><subject>Review</subject><issn>0144-8463</issn><issn>1573-4935</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkUlLBDEUhIMoOi4n75KjIK3ZeslF0MENBMHlHF6nX89EetJj0i34780wOujpUdRHvYIi5Jizc86UuLh-eRaMayYk2yITnpcyU1rm22TCuFJZpQq5R_ZjfGeMJUPtkj3JZVXqUkyIn86h69DPMFLwDW3HYQxI-5YuA1oXXe_pAhtnnUcahwADzlxi2z7QOiDEgVrwFpOCiA1NONAGBljJlWrCOKMJtEOKiodkp4Uu4tHPPSBvtzev0_vs8enuYXr1mFmlyiEDWVhRWNBWNAI0CKWhqnmlbQ21ZAwsFzIvBJQ5Qyu44hLzglXASmh03soDcrnOXY51qm_Rp-qdWQa3gPBlenDmv-Pd3Mz6T1OUUshCpoDTn4DQf4wYB7Nw0WLXgcd-jEaIQkut1-jZGrWhjzFgu3nDmVktZP4slOiTv8027O8k8hsMuI2Y</recordid><startdate>20190930</startdate><enddate>20190930</enddate><creator>Zhang, Xiping</creator><creator>Yang, Hongjian</creator><creator>Zhang, Ruiping</creator><general>Portland Press Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3556-9681</orcidid></search><sort><creationdate>20190930</creationdate><title>Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions</title><author>Zhang, Xiping ; Yang, Hongjian ; Zhang, Ruiping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-a36c26ca9c2d2a9a249a8b189cbab300ac123562a750ec21413e5608a07ad95f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Xiping</creatorcontrib><creatorcontrib>Yang, Hongjian</creatorcontrib><creatorcontrib>Zhang, Ruiping</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bioscience reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Xiping</au><au>Yang, Hongjian</au><au>Zhang, Ruiping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions</atitle><jtitle>Bioscience reports</jtitle><addtitle>Biosci Rep</addtitle><date>2019-09-30</date><risdate>2019</risdate><volume>39</volume><issue>9</issue><issn>0144-8463</issn><eissn>1573-4935</eissn><abstract>Breast cancer (BC) is a malignancy with the highest incidence in women. Great progress has been made in research related to traditional precision medicine for BC. However, many reports have suggested that patients with BC have not benefited a lot from such progress. Thus, we analyze traditional precision medicine strategies for BC, sum up their limitations and challenges, and preliminarily propose future orientations of precision medicine strategies based on a database on drug reaction of patients with BC. According to related research, traditional precision medicine strategies for BC, which are based on molecular subtypes, perform pertinent treatments, new drug research and development according to molecular typing results. Nevertheless, these strategies still have some deficiencies. First, there are very few patients with each molecular subtype, the match ratio of drugs is low. Second, these strategies can not solve the problem of poor drug sensitivity resulting from heterogeneity. The main strategy we put forward in the present paper is based on patients' varying drug reactions. Focusing on treating existing patients and maximizing the utilization of existing drugs, it is expected to not have deficiencies of traditional precision medicine for BC, including low match rate and poor therapeutic efficacy arising from tumor heterogeneity of BC.</abstract><cop>England</cop><pub>Portland Press Ltd</pub><pmid>31387972</pmid><doi>10.1042/BSR20190230</doi><orcidid>https://orcid.org/0000-0002-3556-9681</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0144-8463 |
ispartof | Bioscience reports, 2019-09, Vol.39 (9) |
issn | 0144-8463 1573-4935 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6732363 |
source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Review |
title | Challenges and future of precision medicine strategies for breast cancer based on a database on drug reactions |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T03%3A11%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Challenges%20and%20future%20of%20precision%20medicine%20strategies%20for%20breast%20cancer%20based%20on%20a%20database%20on%20drug%20reactions&rft.jtitle=Bioscience%20reports&rft.au=Zhang,%20Xiping&rft.date=2019-09-30&rft.volume=39&rft.issue=9&rft.issn=0144-8463&rft.eissn=1573-4935&rft_id=info:doi/10.1042/BSR20190230&rft_dat=%3Cproquest_pubme%3E2269399363%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2269399363&rft_id=info:pmid/31387972&rfr_iscdi=true |